<p>Voyager Therapeutics（纳斯达克：VYGR - 获取免费报告）于周一发布了季度财报。该公司报告季度每股收益为（$0.47），超出分析师一致预期的（$0.53）$0.06，Zacks 报道。Voyager Therapeutics 的股本回报率为负 37.65%，净利润率为负 253.49%。</p>
<p>获取 <strong>Voyager Therapeutics</strong> 的提醒：</p>
<h2>Voyager Therapeutics 股票表现</h2>
<ul>
<li>Voyager Therapeutics 股票因与诺华达成交易上涨 30%</li>
</ul>
<p>周一中午交易时，纳斯达克 VYGR 上涨 $0.03，达到 $4.26。该股票交易量为 556,597 股，低于其 573,133 的平均交易量。该公司的 50 日简单移动平均为$4.51，200 日简单移动平均为$3.71。Voyager Therapeutics 的 1 年最低价为$2.64，最高价为$7.44。该股票的市值为 2.363 亿美元，市盈率为-2.30，贝塔值为 0.95。</p>
<h2>内部买卖</h2>
<p>在相关消息中，首席财务官 Nathan D. Jorgensen 于 10 月 3 日星期五出售了 7,666 股公司的股票。该股票以平均价格$4.78 出售，总交易额为$36,643.48。交易后，首席财务官直接持有 123,834 股公司股票，价值约$591,926.52。此次交易使其持股减少了 5.83%。该交易已在向 SEC 的法律文件中披露，SEC 网站上可以访问。4.53% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>一些大型投资者最近调整了对该公司的持股。先锋集团（Vanguard Group Inc.）在第三季度将其在 Voyager Therapeutics 的持股提高了 1.3%。先锋集团目前持有 3,250,066 股公司股票，价值$15,178,000，在此期间又购买了 40,147 股。Geode Capital Management LLC 在第二季度将其在 Voyager Therapeutics 的持股提高了 1.1%。Geode Capital Management LLC 目前持有 1,116,847 股公司股票，价值$3,474,000，在上个季度又收购了 11,929 股。AQR Capital Management LLC 在第一季度将其在 Voyager Therapeutics 的持股提高了 179.3%。AQR Capital Management LLC 目前持有 495,260 股公司股票，价值$1,674,000，在上个季度又购买了 317,927 股。Acadian Asset Management LLC 在第一季度将其在 Voyager Therapeutics 的持股提高了 863.3%。Acadian Asset Management LLC 目前持有 230,708 股公司股票，价值$778,000，在此期间又购买了 206,758 股。最后，汇丰控股（Hsbc Holdings PLC）在第二季度将其在 Voyager Therapeutics 的持股提高了 118.5%。汇丰控股目前持有 148,377 股公司股票，价值$440,000，在上个季度又收购了 80,474 股。目前 48.03% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师观点</h2>
<p>VYGR 最近成为几份研究报告的主题。Wedbush 在 8 月 7 日的研究报告中将 Voyager Therapeutics 的目标股价从$9.00 下调至$8.00，并对该股票给予 “跑赢大盘” 的评级。HC Wainwright 在 9 月 15 日的报告中重申了 “买入” 评级，并将 Voyager Therapeutics 的目标股价设定为$30.00。最后，Weiss Ratings 在 10 月 8 日的研究笔记中重申了对 Voyager Therapeutics 的 “卖出（d）” 评级。六位股票研究分析师对该股票给予了买入评级，一位分析师对公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标股价为$12.96。</p>
<p><strong>阅读我们对 VYGR 的最新分析</strong></p>
<h2>Voyager Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Voyager Therapeutics, Inc.是一家生物技术公司，专注于基因治疗和神经疾病的治疗。该公司的主要临床候选药物是 VY-TAU01，一种针对阿尔茨海默病的抗 tau 抗体项目。其产品管线包括超氧化物歧化酶 1 沉默基因治疗，正在进行肌萎缩侧索硬化症的临床前试验；tau 沉默基因治疗，正在进行阿尔茨海默病的临床前试验；以及针对阿尔茨海默病的抗淀粉样蛋白基因治疗，正在进行临床前试验。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Voyager Therapeutics</li>
<li>突破股票：它们是什么以及如何识别它们</li>
<li>Monday.com 因疯狂抛售开启了代际机会</li>
<li>如何计算期权利润</li>
<li>股票下跌中的盈利胜利：D-Wave 发生了什么？</li>
<li>投资者需要知道的以击败市场的信息</li>
<li>3 只在市场回调时显示相对强势的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VllHUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VllHUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Voyager Therapeutics 吗？</h2>
<p>在考虑投资 Voyager Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Voyager Therapeutics 并不在名单上。</p>
<p>虽然 Voyager Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看五只股票</p>

VYGR

<p>Voyager Therapeutics（纳斯达克代码：VYGR）报告每股收益为（$0.47），超出预期的（$0.53）$0.06。该公司的股本回报率为负 37.65%，净利润率为负 253.49%。在财报发布后，Voyager 的股票上涨了 30%，达到$4.26。机构投资者持有该公司 48.03% 的股份，主要公司近期对持股进行了调整。分析师的评级不一，平均目标价为$12.96，显示出 “适度买入” 的情绪</p>

<p>Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.06, Zacks reports. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%.</p>
<div class="lb-trans"><p>Voyager Therapeutics（纳斯达克：VYGR - 获取免费报告）于周一发布了季度财报。该公司报告季度每股收益为（$0.47），超出分析师一致预期的（$0.53）$0.06，Zacks 报道。Voyager Therapeutics 的股本回报率为负 37.65%，净利润率为负 253.49%。</p>
</div><p>Get <strong>Voyager Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Voyager Therapeutics</strong> 的提醒：</p>
</div><h2>Voyager Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Voyager Therapeutics 股票表现</h2>
</div><ul>
<li>Voyager Therapeutics stock pops 30% on deal with Novartis</li>
</ul>
<div class="lb-trans"><ul>
<li>Voyager Therapeutics 股票因与诺华达成交易上涨 30%</li>
</ul>
</div><p>NASDAQ VYGR traded up $0.03 during mid-day trading on Monday, reaching $4.26. 556,597 shares of the stock were exchanged, compared to its average volume of 573,133. The business's fifty day simple moving average is $4.51 and its 200 day simple moving average is $3.71. Voyager Therapeutics has a 1-year low of $2.64 and a 1-year high of $7.44. The stock has a market capitalization of $236.30 million, a PE ratio of -2.30 and a beta of 0.95.</p>
<div class="lb-trans"><p>周一中午交易时，纳斯达克 VYGR 上涨 $0.03，达到 $4.26。该股票交易量为 556,597 股，低于其 573,133 的平均交易量。该公司的 50 日简单移动平均为$4.51，200 日简单移动平均为$3.71。Voyager Therapeutics 的 1 年最低价为$2.64，最高价为$7.44。该股票的市值为 2.363 亿美元，市盈率为-2.30，贝塔值为 0.95。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, CFO Nathan D. Jorgensen sold 7,666 shares of the business's stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $4.78, for a total transaction of $36,643.48. Following the transaction, the chief financial officer directly owned 123,834 shares of the company's stock, valued at approximately $591,926.52. The trade was a 5.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.53% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Nathan D. Jorgensen 于 10 月 3 日星期五出售了 7,666 股公司的股票。该股票以平均价格$4.78 出售，总交易额为$36,643.48。交易后，首席财务官直接持有 123,834 股公司股票，价值约$591,926.52。此次交易使其持股减少了 5.83%。该交易已在向 SEC 的法律文件中披露，SEC 网站上可以访问。4.53% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in Voyager Therapeutics by 1.3% during the third quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company's stock worth $15,178,000 after purchasing an additional 40,147 shares during the period. Geode Capital Management LLC increased its position in shares of Voyager Therapeutics by 1.1% during the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company's stock valued at $3,474,000 after acquiring an additional 11,929 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Voyager Therapeutics by 179.3% in the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company's stock worth $1,674,000 after buying an additional 317,927 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company's stock worth $778,000 after purchasing an additional 206,758 shares during the period. Finally, Hsbc Holdings PLC increased its holdings in Voyager Therapeutics by 118.5% in the 2nd quarter. Hsbc Holdings PLC now owns 148,377 shares of the company's stock worth $440,000 after acquiring an additional 80,474 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了对该公司的持股。先锋集团（Vanguard Group Inc.）在第三季度将其在 Voyager Therapeutics 的持股提高了 1.3%。先锋集团目前持有 3,250,066 股公司股票，价值$15,178,000，在此期间又购买了 40,147 股。Geode Capital Management LLC 在第二季度将其在 Voyager Therapeutics 的持股提高了 1.1%。Geode Capital Management LLC 目前持有 1,116,847 股公司股票，价值$3,474,000，在上个季度又收购了 11,929 股。AQR Capital Management LLC 在第一季度将其在 Voyager Therapeutics 的持股提高了 179.3%。AQR Capital Management LLC 目前持有 495,260 股公司股票，价值$1,674,000，在上个季度又购买了 317,927 股。Acadian Asset Management LLC 在第一季度将其在 Voyager Therapeutics 的持股提高了 863.3%。Acadian Asset Management LLC 目前持有 230,708 股公司股票，价值$778,000，在此期间又购买了 206,758 股。最后，汇丰控股（Hsbc Holdings PLC）在第二季度将其在 Voyager Therapeutics 的持股提高了 118.5%。汇丰控股目前持有 148,377 股公司股票，价值$440,000，在上个季度又收购了 80,474 股。目前 48.03% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>VYGR has been the topic of several recent research reports. Wedbush lowered their price target on shares of Voyager Therapeutics from $9.00 to $8.00 and set an &#34;outperform&#34; rating on the stock in a research report on Thursday, August 7th. HC Wainwright restated a &#34;buy&#34; rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Monday, September 15th. Finally, Weiss Ratings restated a &#34;sell (d)&#34; rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $12.96.</p>
<div class="lb-trans"><p>VYGR 最近成为几份研究报告的主题。Wedbush 在 8 月 7 日的研究报告中将 Voyager Therapeutics 的目标股价从$9.00 下调至$8.00，并对该股票给予 “跑赢大盘” 的评级。HC Wainwright 在 9 月 15 日的报告中重申了 “买入” 评级，并将 Voyager Therapeutics 的目标股价设定为$30.00。最后，Weiss Ratings 在 10 月 8 日的研究笔记中重申了对 Voyager Therapeutics 的 “卖出（d）” 评级。六位股票研究分析师对该股票给予了买入评级，一位分析师对公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标股价为$12.96。</p>
</div><p><strong>Read Our Latest Analysis on VYGR</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 VYGR 的最新分析</strong></p>
</div><h2>Voyager Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Voyager Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.</p>
<div class="lb-trans"><p>Voyager Therapeutics, Inc.是一家生物技术公司，专注于基因治疗和神经疾病的治疗。该公司的主要临床候选药物是 VY-TAU01，一种针对阿尔茨海默病的抗 tau 抗体项目。其产品管线包括超氧化物歧化酶 1 沉默基因治疗，正在进行肌萎缩侧索硬化症的临床前试验；tau 沉默基因治疗，正在进行阿尔茨海默病的临床前试验；以及针对阿尔茨海默病的抗淀粉样蛋白基因治疗，正在进行临床前试验。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Voyager Therapeutics</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Monday.com Opens Generational Opportunity With Manic Sell-Off</li>
<li>How to Calculate Options Profits</li>
<li>An Earnings Win With a Stock Slump: What's Happening With D-Wave?</li>
<li>What Investors Need to Know to Beat the Market</li>
<li>3 Stocks Showing Relative Strength as Markets Pull Back</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Voyager Therapeutics</li>
<li>突破股票：它们是什么以及如何识别它们</li>
<li>Monday.com 因疯狂抛售开启了代际机会</li>
<li>如何计算期权利润</li>
<li>股票下跌中的盈利胜利：D-Wave 发生了什么？</li>
<li>投资者需要知道的以击败市场的信息</li>
<li>3 只在市场回调时显示相对强势的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VllHUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=VYGR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Voyager Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Voyager Therapeutics 吗？</h2>
</div><p>Before you consider Voyager Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Voyager Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Voyager Therapeutics 并不在名单上。</p>
</div><p>While Voyager Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Voyager Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看五只股票</p>
</div>

Voyager Therapeutics (NASDAQ:VYGR) 公布了收益结果，每股收益比预期高出 0.06 美元